首页> 美国卫生研究院文献>Cardiovascular Diabetology >Safety tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

【2h】

Safety tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

机译：Empagliflozin单药治疗初治2型糖尿病患者的安全性耐受性和对心血管代谢危险因素的影响：III期随机对照试验的双盲扩展

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundTo investigate the long-term efficacy and safety of empagliflozin monotherapy compared with placebo and sitagliptin in drug-naïve patients with type 2 diabetes mellitus.

机译：背景：为了研究恩帕格列净单一疗法与安慰剂和西他列汀相比在未经药物治疗的2型糖尿病患者中的长期疗效和安全性。

著录项

期刊名称 Cardiovascular Diabetology
作者
Michael Roden; Ludwig Merker; Anita Vedel Christiansen; Flavien Roux; Afshin Salsali; Gabriel Kim; Peter Stella; Hans J. Woerle; Uli C. Broedl;
展开▼
作者单位

展开▼
年(卷),期 2015(14),-1
年度 2015
页码 154
总页数 11
原文格式 PDF
正文语种
中图分类心血管疾病 ;
关键词
Type 2 diabetes Empagliflozin SGLT2 inhibitor Safety Blood pressure;

机译：2型糖尿病;依帕列净;SGLT2抑制剂;安全性;血压;

相似文献

外文文献
中文文献
专利

1. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na?ve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial [J] . Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Cardiovascular Diabetology . 2015 ,第1期

机译：初治型2型糖尿病患者使用恩帕格列净单药治疗的安全性，耐受性及对心血管代谢危险因素的影响：III期随机对照试验的双盲扩展
2. Long-term efficacy and safety of empagliflozin monotherapy in drug-na?ve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study [J] . Sunil Gupta, Shehla Shaikh, Pooja Joshi, Indian Journal of Endocrinology and Metabolism . 2017 ,第2期

机译：恩帕格列净单药治疗印度亚组中未用过药物的2型糖尿病患者的长期疗效和安全性：一项为期7.6周的iii期，双盲，随机对照研究的结果
3. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension [J] . A. H. Barnett, S. Pate!, R. Harper, Diabetes, obesity & metabolism . 2012 ,第12期

机译：利格列汀单药治疗不适合二甲双胍的2型糖尿病患者：一项为期18周的随机，双盲，安慰剂对照的III期临床试验，并进行了34周的主动对照扩展
4. Randomised Controlled Trial of an In-Home Monitoring Intervention to Improve Health Outcomes for Type 2 Diabetes: Study Protocol [C] . Karen CARLISLE, Robin WARREN, Paul SCUFFHAM, Global Telehealth (Conference) . 2012

机译：随机对照试验的内部监测干预以改善2型糖尿病的健康结果：研究方案
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Efficacy and safety of fasiglifam (TAK-875) a G protein-coupled receptor 40 agonist in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized double-blind placebo-controlled phase III trial [O] . K Kaku, K Enya, R Nakaya, -1

机译：在饮食和运动控制不充分的日本2型糖尿病患者中G蛋白偶联受体40激动剂Fasiglifam（TAK-875）的疗效和安全性：一项随机双盲安慰剂对照的III期临床试验
7. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial [O] . 2015

机译：Empagliflozin单药治疗初治2型糖尿病患者的安全性，耐受性和对心血管代谢危险因素的影响：III期随机对照试验的双盲扩展

Safety tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅